Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Liana Asatryan, PhD

    TitleResearch Assistant Professor
    SchoolSchool of Pharmacy
    DepartmentClinical Pharmacy and Pharmaceutical Econ. and Policy
    AddressPSC 508
    Health Sciences Campus
    Los Angeles California 90089-9121
    Phone+1 323 442 1495
    vCardDownload vCard

      Collapse Overview 
      Collapse Overview
      Dr. Liana Asatryan is currently a Research Assistant Professor in the Titus Family Department of Clinical Pharmacy and Pharmaceutical Economics & Policy at the USC School of Pharmacy.

      Dr. Asatryan earned her PhD in Biochemistry from the Institute of Molecular Biology, National Academy of Sciences of Armenia in 1994. From 1997 to 1999, she continued her research as a National Institutes of Health postdoctoral fellow at USC School of Pharmacy. In 2009, Dr. Asatryan completed the Graduate Certificate in Clinical Research Design & Management in Regulatory Science at USC. In addition to her research responsibilities, Dr. Asatryan currently lectures in the Masters of Management of Drug Development in the International Center of Regulatory Science at USC.

      Dr. Asatryan is a recipient of KO1 Career Development Grant from National Institutes of Alcoholism and Alcohol Abuse.

      Since 2008, she has supervised the day-to-day operations of the Lentiviral Core Laboratory of the School of Pharmacy.

      Collapse ORNG Applications 
      Collapse Websites
      Collapse In The News

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Huynh N, Arabian N, Naito A, Louie S, Jakowec MW, Asatryan L, Davies DL. Preclinical development of moxidectin as a novel therapeutic for alcohol use disorder. Neuropharmacology. 2017 Feb; 113(Pt A):60-70. PMID: 27641072.
        View in: PubMed
      2. Khoja S, Shah V, Garcia D, Asatryan L, Jakowec MW, Davies DL. Role of purinergic P2X4 receptors in regulating striatal dopamine homeostasis and dependent behaviors. J Neurochem. 2016 Oct; 139(1):134-48. PMID: 27402173; PMCID: PMC5037001 [Available on 10/01/17].
      3. Huynh N, Arabian N, Lieu D, Asatryan L, Davies DL. Utilizing an Orally Dissolving Strip for Pharmacological and Toxicological Studies: A Simple and Humane Alternative to Oral Gavage for Animals. J Vis Exp. 2016 Mar 23; (109):e53770. PMID: 27078261.
        View in: PubMed
      4. Menschikowski M, Hagelgans A, Nacke B, Jandeck C, Mareninova OA, Asatryan L, Siegert G. Epigenetic control of group V phospholipase A2 expression in human malignant cells. Tumour Biol. 2016 Jun; 37(6):8097-105. PMID: 26715269.
        View in: PubMed
      5. Asatryan L, Khoja S, Rodgers KE, Alkana RL, Tsukamoto H, Davies DL. Chronic ethanol exposure combined with high fat diet up-regulates P2X7 receptors that parallels neuroinflammation and neuronal loss in C57BL/6J mice. J Neuroimmunol. 2015 Aug 15; 285:169-79. PMID: 26198936; PMCID: PMC4512299.
      6. Naito A, Muchhala KH, Trang J, Asatryan L, Trudell JR, Homanics GE, Alkana RL, Davies DL. Manipulations of extracellular Loop 2 in a1 GlyR ultra-sensitive ethanol receptors (USERs) enhance receptor sensitivity to isoflurane, ethanol, and lidocaine, but not propofol. Neuroscience. 2015 Jun 25; 297:68-77. PMID: 25827497; PMCID: PMC4428915.
      7. Naito A, Muchhala KH, Asatryan L, Trudell JR, Homanics GE, Perkins DI, Davies DL, Alkana RL. Glycine and GABA(A) ultra-sensitive ethanol receptors as novel tools for alcohol and brain research. Mol Pharmacol. 2014 Dec; 86(6):635-46. PMID: 25245406; PMCID: PMC4244596.
      8. Yardley MM, Neely M, Huynh N, Asatryan L, Louie SG, Alkana RL, Davies DL. Multiday administration of ivermectin is effective in reducing alcohol intake in mice at doses shown to be safe in humans. Neuroreport. 2014 Sep 10; 25(13):1018-23. PMID: 25004078; PMCID: PMC4126080.
      9. Franklin KM, Asatryan L, Jakowec MW, Trudell JR, Bell RL, Davies DL. P2X4 receptors (P2X4Rs) represent a novel target for the development of drugs to prevent and/or treat alcohol use disorders. Front Neurosci. 2014; 8:176. PMID: 25009459; PMCID: PMC4068020.
      10. Wyatt LR, Finn DA, Khoja S, Yardley MM, Asatryan L, Alkana RL, Davies DL. Contribution of P2X4 receptors to ethanol intake in male C57BL/6 mice. Neurochem Res. 2014 Jun; 39(6):1127-39. PMID: 24671605; PMCID: PMC4031031.
      11. Asatryan L, Yardley MM, Khoja S, Trudell JR, Hyunh N, Louie SG, Petasis NA, Alkana RL, Davies DL. Avermectins differentially affect ethanol intake and receptor function: implications for developing new therapeutics for alcohol use disorders. Int J Neuropsychopharmacol. 2014 Jun; 17(6):907-16. PMID: 24451653; PMCID: PMC4209915.
      12. Menschikowski M, Hagelgans A, Fuessel S, Mareninova OA, Asatryan L, Wirth MP, Siegert G. Serum amyloid A, phospholipase A2-IIA and C-reactive protein as inflammatory biomarkers for prostate diseases. Inflamm Res. 2013 Dec; 62(12):1063-72. PMID: 24061501.
        View in: PubMed
      13. Popova M, Trudell J, Li K, Alkana R, Davies D, Asatryan L. Tryptophan 46 is a site for ethanol and ivermectin action in P2X4 receptors. Purinergic Signal. 2013 Dec; 9(4):621-32. PMID: 23817978; PMCID: PMC3889384.
      14. Bortolato M, Yardley MM, Khoja S, Godar SC, Asatryan L, Finn DA, Alkana RL, Louie SG, Davies DL. Pharmacological insights into the role of P2X4 receptors in behavioural regulation: lessons from ivermectin. Int J Neuropsychopharmacol. 2013 Jun; 16(5):1059-70. PMID: 23174033; PMCID: PMC3593990.
      15. Yardley MM, Wyatt L, Khoja S, Asatryan L, Ramaker MJ, Finn DA, Alkana RL, Huynh N, Louie SG, Petasis NA, Bortolato M, Davies DL. Ivermectin reduces alcohol intake and preference in mice. Neuropharmacology. 2012 Aug; 63(2):190-201. PMID: 22465817; PMCID: PMC3372603.
      16. Perkins DI, Trudell JR, Asatryan L, Davies DL, Alkana RL. Charge and geometry of residues in the loop 2 ß hairpin differentially affect agonist and ethanol sensitivity in glycine receptors. J Pharmacol Exp Ther. 2012 May; 341(2):543-51. PMID: 22357974; PMCID: PMC3336819.
      17. Asatryan L, Nam HW, Lee MR, Thakkar MM, Saeed Dar M, Davies DL, Choi DS. Implication of the purinergic system in alcohol use disorders. Alcohol Clin Exp Res. 2011 Apr; 35(4):584-94. PMID: 21223299; PMCID: PMC3076125.
      18. Ostrovskaya O, Asatryan L, Wyatt L, Popova M, Li K, Peoples RW, Alkana RL, Davies DL. Ethanol is a fast channel inhibitor of P2X4 receptors. J Pharmacol Exp Ther. 2011 Apr; 337(1):171-9. PMID: 21212160; PMCID: PMC3063738.
      19. Asatryan L, Popova M, Perkins D, Trudell JR, Alkana RL, Davies DL. Ivermectin antagonizes ethanol inhibition in purinergic P2X4 receptors. J Pharmacol Exp Ther. 2010 Sep 01; 334(3):720-8. PMID: 20543096; PMCID: PMC2939657.
      20. Popova M, Asatryan L, Ostrovskaya O, Wyatt LR, Li K, Alkana RL, Davies DL. A point mutation in the ectodomain-transmembrane 2 interface eliminates the inhibitory effects of ethanol in P2X4 receptors. J Neurochem. 2010 Jan; 112(1):307-17. PMID: 19878433; PMCID: PMC2809143.
      21. Perkins DI, Trudell JR, Crawford DK, Asatryan L, Alkana RL, Davies DL. Loop 2 structure in glycine and GABA(A) receptors plays a key role in determining ethanol sensitivity. J Biol Chem. 2009 Oct 02; 284(40):27304-14. PMID: 19656948; PMCID: PMC2785658.
      22. Hamilton RT, Asatryan L, Nilsen JT, Isas JM, Gallaher TK, Sawamura T, Hsiai TK. LDL protein nitration: implication for LDL protein unfolding. Arch Biochem Biophys. 2008 Nov 01; 479(1):1-14. PMID: 18713619; PMCID: PMC2649963.
      23. Asatryan L, Popova M, Woodward JJ, King BF, Alkana RL, Davies DL. Roles of ectodomain and transmembrane regions in ethanol and agonist action in purinergic P2X2 and P2X3 receptors. Neuropharmacology. 2008 Oct; 55(5):835-43. PMID: 18639563; PMCID: PMC2629788.
      24. Davies DL, Asatryan L, Kuo ST, Woodward JJ, King BF, Alkana RL, Xiao C, Ye JH, Sun H, Zhang L, Hu XQ, Hayrapetyan V, Lovinger DM, Machu TK. Effects of ethanol on adenosine 5'-triphosphate-gated purinergic and 5-hydroxytryptamine receptors. Alcohol Clin Exp Res. 2006 Feb; 30(2):349-58. PMID: 16441284; PMCID: PMC1448702.
      25. Ahmed W, Orasanu G, Nehra V, Asatryan L, Rader DJ, Ziouzenkova O, Plutzky J. High-density lipoprotein hydrolysis by endothelial lipase activates PPARalpha: a candidate mechanism for high-density lipoprotein-mediated repression of leukocyte adhesion. Circ Res. 2006 Mar 03; 98(4):490-8. PMID: 16439686; PMCID: PMC4231787.
      26. Hwang J, Hodis HN, Hsiai TK, Asatryan L, Sevanian A. Role of annexin II in estrogen-induced macrophage matrix metalloproteinase-9 activity: the modulating effect of statins. Atherosclerosis. 2006 Nov; 189(1):76-82. PMID: 16386257.
        View in: PubMed
      27. Asatryan L, Hamilton RT, Isas JM, Hwang J, Kayed R, Sevanian A. LDL phospholipid hydrolysis produces modified electronegative particles with an unfolded apoB-100 protein. J Lipid Res. 2005 Jan; 46(1):115-22. PMID: 15489541; PMCID: PMC3383313.
      28. Ziouzenkova O, Asatryan L, Sahady D, Orasanu G, Perrey S, Cutak B, Hassell T, Akiyama TE, Berger JP, Sevanian A, Plutzky J. Dual roles for lipolysis and oxidation in peroxisome proliferation-activator receptor responses to electronegative low density lipoprotein. J Biol Chem. 2003 Oct 10; 278(41):39874-81. PMID: 12878589; PMCID: PMC4231711.
      29. Asatryan L, Ziouzenkova O, Duncan R, Sevanian A. Heme and lipid peroxides in hemoglobin-modified low-density lipoprotein mediate cell survival and adaptation to oxidative stress. Blood. 2003 Sep 01; 102(5):1732-9. PMID: 12750169.
        View in: PubMed
      30. Ziouzenkova O, Perrey S, Asatryan L, Hwang J, MacNaul KL, Moller DE, Rader DJ, Sevanian A, Zechner R, Hoefler G, Plutzky J. Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase. Proc Natl Acad Sci U S A. 2003 Mar 04; 100(5):2730-5. PMID: 12606719; PMCID: PMC151409.
      31. Ziouzenkova O, Asatryan L, Tetta C, Wratten ML, Hwang J, Sevanian A. Oxidative stress during ex vivo hemodialysis of blood is decreased by a novel hemolipodialysis procedure utilizing antioxidants. Free Radic Biol Med. 2002 Jul 15; 33(2):248-58. PMID: 12106820.
        View in: PubMed
      32. Sevanian A, Asatryan L. LDL modification during hemodialysis. Markers for oxidative stress. Contrib Nephrol. 2002; (137):386-95. PMID: 12101983.
        View in: PubMed
      33. Das A, Asatryan L, Reddy MA, Wass CA, Stins MF, Joshi S, Bonventre JV, Kim KS. Differential role of cytosolic phospholipase A2 in the invasion of brain microvascular endothelial cells by Escherichia coli and Listeria monocytogenes. J Infect Dis. 2001 Sep 15; 184(6):732-7. PMID: 11517434.
        View in: PubMed
      34. Ziouzenkova O, Asatryan L, Akmal M, Tetta C, Wratten ML, Loseto-Wich G, Jürgens G, Heinecke J, Sevanian A. Oxidative cross-linking of ApoB100 and hemoglobin results in low density lipoprotein modification in blood. Relevance to atherogenesis caused by hemodialysis. J Biol Chem. 1999 Jul 02; 274(27):18916-24. PMID: 10383389.
        View in: PubMed
      35. Ziouzenkova O, Asatryan L, Sevanian A. Oxidative stress resulting from hemolysis and formation of catalytically active hemoglobin: protective strategies. Int J Clin Pharmacol Ther. 1999 Mar; 37(3):125-32. PMID: 10190760.
        View in: PubMed
      36. Sevanian A, Asatryan L, Ziouzenkova O. Low density lipoprotein (LDL) modification: basic concepts and relationship to atherosclerosis. Blood Purif. 1999; 17(2-3):66-78. PMID: 10449864.
        View in: PubMed
      37. Spirin AS, Asatryan L. The effect of ribosomal peptidyl-transferase inhibitors is antagonized by elongation factor G with GTP. FEBS Lett. 1976 Nov; 70(1):101-4. PMID: 791676.
        View in: PubMed
      38. Asatryan L, Spirin AS. Non-enzymatic translocation in ribosomes from streptomycin-resistant mutants of Escherichia coli. Mol Gen Genet. 1975 Jul 10; 138(4):315-21. PMID: 1097889.
        View in: PubMed